Ofatumumab Early Treatment for High-Risk Treatment-Naive, Early Stage (0-II) Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 21 Sep 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 07 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 03 May 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.